TABLE 5.
Group | Normal | Model | SASP | LF-HFY06 |
TNF-α (ng/L) | 993 ± 82a | 1,415 ± 45b | 1,168 ± 82c | 1,229 ± 59c |
IL-1β (ng/L) | 76.9 ± 4.9 a | 96.6 ± 6.4b | 85.8 ± 5.8c | 84.1 ± 4.7c |
IL-6 (pg/L) | 275 ± 16a | 332 ± 15b | 278 ± 19a | 280 ± 15a |
IL-12 (ng/L) | 138 ± 7a | 167 ± 8b | 159 ± 6bc | 150 ± 9c |
IFN-γ (ng/L) | 841 ± 76a | 1485 ± 122b | 1,206 ± 67c | 1,103 ± 65c |
IL-10 (pg/L) | 1,437 ± 84a | 1,014 ± 113b | 1,257 ± 60c | 1,366 ± 68ac |
Values are presented as the mean ± standard deviation (n = 8/group). Normal, mice were treated with saline; Model, mice were treated with 5% DSS; SASP, mice were treated with 50 mg/mL of salicylazosulfapyridine + 5% DSS; LF-HFY06, mice were treated with 1.0 × 109 CFU/mL of LF-HFY06 + 5% DSS; a–csignificant difference (P < 0.05) was indicated by different letters in the same row after Tukey’s test.